Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Pick a strategy above and run the backtest to see its simulated performance on MLTX.
Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.
MoonLake Immunotherapeutics (MLTX) is trading at $10.77, down 1.64% on the day. Its market value of $916.60M makes it the 3298th largest of the 3753 companies we follow.
Over the past 52 weeks it has traded between $8.80 and $23.29, so it sits 53.8% below the top of that range. Holders are ahead 18.4% over twelve months, but down 46.0% across the last three months.
On the chart it has slipped under both the 50-day ($14.66) and 200-day ($16.72) moving averages; RSI is 25, which some call oversold, and the last 30 sessions moved at roughly 46% annualized volatility.
In the quarter ended Jun 2026 the company brought in $0.00 of revenue, and a net loss of $61.81M.
7 analysts follow the stock and the average call is "buy". The mean target, $34.50, sits 220.3% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 3 factors below, ranked against the 3752 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Trading closer to its 52-week high than most peers scores higher.
7 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
MLTX is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $34.50, 220.3% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $11.79, so shares trade 8.6% below that estimate. On earnings multiple, it sits in the 90th percentile of its own five-year valuation range (pricier than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -10.8% | Bearish |
| Price vs 50-day average | -26.5% | Bearish |
| Price vs 200-day average | -35.6% | Bearish |
| 50-day vs 200-day | 50d below 200d | Bearish |
| RSI (14) | 24.8 | Neutral |
| MACD (12,26,9) | -1.04 | Bullish |
| Bollinger band position | 5% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Oct 8, 2026 8:10 am ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 3,752 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$10.77 is the latest print for MLTX, a move of -1.64% against yesterday's close of $10.95. Today's low and high so far: $10.71 and $11.29.
Equity value comes to $916.60M at the current price. By that measure it is number 3298 of the 3753 names in our coverage.
The year's floor is $8.80 and the ceiling $23.29. Shares are 53.8% away from that ceiling.
Our data shows no dividend paid by MoonLake Immunotherapeutics over the trailing twelve months.
Of 7 analysts, 100% say buy, 0% hold and 0% sell. Price targets average $34.50, with the most cautious at $30.00 and the most optimistic at $50.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on MLTX.